Daiichi Sankyo and AstraZeneca’s Enhertu gains NMPA approval for HER2 GEJ
The approval is supported by data from the DESTINY-Gastric04 Phase III trial.
Syngene Thematic ADC WP
Ipsen outlays $1bn for China-based Simcere’s preclinical ADC
Takeda and Innovent fulfil close conditions for ADC and IO therapies
FDA awards record number of review designations to ADCs in 2024
CPHI 2025: linker innovation paves the way for a wave of new ADCs
Solve Therapeutics raises $120m as MSD joins list of backers
MSD secures $700m for broad-cancer ADC asset
IntoCell and Xcellon Biologics to advance ADC development
